Lipid nanocapsules (LNCs) represent a stable, biocompatible and worthwhile drug delivery system, demonstrating significant potential as gene/drug delivery platforms for cancer therapy. Imatinib, a potent tyrosine kinase inhibitor, has revolutionized the therapy of malignancies resulting from abnormal tyrosine kinase activity. However, its Clinical effectiveness in cancer treatment is h...

background and objective: gliomas are the most common primary brain tumors. despite therapeutic advances, the majority of gliomas do not respond to either chemo or radiotherapy. cd117, the gene product of c-kit has been expressed in cells of glial tumors. because gastrointestinal stromal tumors (gists) that express cd117 respond dramatically to treatment with tyrosine kinase inhibitors, identif...

Background and Aims: Multiple myeloma is a malignant proliferation of plasma cells derived from a single clone. The tumor, its products and the host response lead to organ damages. Some factors that are responsible in its pathogenesis are recognized. As FMS like Tyrosine Kinase 3 receptor (FLT3) mutation has been proved as a determining factor in leukemic patients the goal of this study was to ...

it has been observed that lung cancer either non-small cell or small cell is responsible for eye metastases. this form of metastases in several cases was the first manifestation of the disease and further investigation led to the diagnosis of the underlying malignancy. both types of lung cancer are equally responsible for this demonstration. furthermore; both chemotherapy and tyrosine kinase in...

imatinib is an orally administered tyrosine kinase inhibitor which inhibits the bcr-abl protein-tyrosine kinase with high selectivity. imatinib is rapidly absorbed from the gut, after oral intake and has an almost absolute bioavailability of 98%. the metabolism of imatinib is mediated by the cytochrome p450 (cyp) isoenzymes in the liver and gut wall. cgp74588 is a major active metabolite of ima...

Chronic myeloid leukemia (CML) is a myeloproliferative malignancy due to the formation of BCR-ABL fusion gene in chronic leukemia. This condition causes excessive cell proliferation, resulting an increase number leukocytes. Tyrosine Kinase Inhibitor (TKI) first-line therapy that helps reduce percentage patients with study was conducted determine differences hematological profiles (hemoglobin le...

introduction: gastrointestinal stromal tumors (gists) are the most common mesenchymal neoplasms of the gastrointestinal tract. gist has been shown to over-express c-kit (cd117), the receptor tyrosine kinase. imatinib (sti571 or glivec) is a new type of tyrosine kinase inhibitor that selectively inhibits various tyrosine kinases and has been successfully used to treat gist. in this study we have...